14 . 01 .2026
Press release
TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics
17 . 12 .2025
Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis
11 . 12 .2025
Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin
11 . 12 .2025
News story
GAIN ASCENT Summit, our training program for emerging injectors, marks the end of GAIN's first decade
05 . 12 .2025
Press release
Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body
04 . 12 .2025
Press release
Galderma secures ‘BBB’ credit rating with positive outlook from S&P Global Ratings